Resumo
Objetivo: Analisar as diferentes condutas terapêuticas, relacionadas principalmente ao uso de corticosteroides, a serem tomadas diante de um paciente com síndrome HELLP. Métodos: Esta revisão bibliográfica integrativa utilizou o PubMed, o Cochrane e o Science Direct como plataformas eletrônicas de pesquisa, elegendo artigos publicados entre os anos de 2002 e 2021. Os descritores utilizados foram “HELLP syndrome”, “therapy” e “management”. Os critérios de inclusão foram artigos de ensaios clínicos, randomizados ou não randomizados, estudos de caso-controle, estudo de coorte, livre acesso, publicados em inglês, português, espanhol. Resultados: Foram selecionados 16 artigos, de um total de 1.340 artigos, incialmente, identificados. Dos artigos analisados foram descritos o uso de quatro corticosteroides distintos no manejo da síndrome HELLP, sendo os dois mais utilizados a dexametasona e a betametasona e os outros dois, menos utilizados, a prednisolona e a metilprednisolona. Considerações finais: Dentre os quatro fármacos disponíveis, sugere-se a dexametasona como a principal droga de escolha para a administração no período pós-parto, uma vez que resulta em maiores benefícios para a recuperação da gestante.
Referências
ALMEIDA WS, et al. Avaliação dos resultados neonatais e fatores associados em gestantes com pré-eclâmpsia grave: uma revisão sistemática. Revista Eletrônica Acervo Saúde, 2021; 13(2): e5799.
ASTUDILLO R, et al. Pregnancy Hypertension: An International Journal of Women’s Cardiovascular Health Expectant management in pregnant women with early and severe preeclampsia and concomitant risk factors. Pregnancy Hypertens An Int J Women’s Cardiovasc Heal, 2013; 3(4): 235–41.
BARNHART L. HELLP Syndrome and the Effects on the Neonate. Neo Network, 2015; 34(5): 269–73.
CAVAIGNAC-VITALIS M, et al. Conservative versus active management in HELLP syndrome: results from a cohort study. ST AC, 2017; 7058.
CLARKE DS e NELSON-PIERCY C. Pre-eclampsia and HELLP syndrome. Anaesth Intensive Care Med, 2008; 9(3): 110–4.
COELHO LMC e SIQUEIRA EC. Distúrbios hipertensivos na gravidez: pré-eclâmpsia, eclâmpsia e síndrome HELLP. Revista Eletrônica Acervo Saúde, 2022; 15(8): e10681.
FITZPATRICK KE, et al. Risk Factors, Management, and Outcomes of Hemolysis, Elevated Liver Enzymes, and Low Platelets Syndrome and Elevated Liver Enzymes, Low Platelets Syndrome. Obstetrics & Gynecology, 2014; 123(3): 618–27.
FONSECA JE, et al. Dexamethasone for the treatment of class I HELLP syndrome: A double- blind, placebo-controlled, multicenter, randomized clinical trial. Pregnancy Hypertens, 2019; 17: 158–64.
HARAM K, et al. The HELLP syndrome: Clinical issues and management. BMC Pregnancy and Childbirth, 2009; 9(8): 1–15.
IOST ARJ, et al. Biomarcadores e pré-eclâmpsia: uma revisão integrativa. Revista Eletrônica Acervo Médico, 2022; 11: e10389.
KANG S, et al. Effectiveness of high-dose glucocorticoids on hemolysis, elevating liver enzymes, and reducing platelets syndrome. Journal of International Medical Research, 2018; 0(0): 1-10.
KATZ L, et al. COHELLP: collaborative randomized controlled trial on corticosteroids in HELLP syndrome. Reproductive Health Journal, 2013; 10(28): 1–6.
MACEDO MBB, et al. Síndrome de HELLP: parâmetros diagnósticos e tratamento oportuno. Revista Eletrônica Acervo Médico, 2022; 19: e11122.
MAGED AM, et al. Maternal, fetal and neonatal outcome among different types of hypertensive disorders associating pregnancy needing intensive care management. The Journal of Maternal-Fetal & Neonatal Medicine, 2018; 7058.
MAGED AM, et al. Maternal, fetal and neonatal outcome among different types of hypertensive disorders associating pregnancy needing intensive care management. The Journal of Maternal-Fetal & Neonatal Medicine, 2018; 7058.
MARIA L, et al. Revisiting HELLP syndrome. Clin Chim Acta, 2015; 451: 117–20.
MARTIN JN e MORRIS RF. Preeclampsia-Spectrum Hypertensive Disorders of Pregnancy: Gestational Hypertension, Preeclampsia, Eclampsia, Chronic Hypertension, and HELLP Syndrome. In: Sex Differences in Cardiovascular Physiology and Pathophysiology. Elsevier Inc, 2019; 121–36.
NUNES F, et al. CORTICOTERAPIA NA SÍNDROME DE HELLP (Hemólise, Enzimas Hepáticos Elevados e Trombocitopenia). Acta Med Port, 2004; 177–82.
O'BRIEN JM, et al. Maternal benefit of corticosteroid therapy in patients with HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome: impact on the rate of regional anesthesia. Am J Obstet Gynecol, 2002; 186(3): 475-479.
OSMANAGAOGLU MA, et al. Maternal outcome in HELLP syndrome requiring intensive care management in a Turkish hospital. Sao Paulo Med J, 2006; 124(2): 85–9.
OZER A e SERDAR MK. The effects of betamethasone treatment on clinical and laboratory features of pregnant women with HELLP syndrome. Arch Gynecol Obstet., 2009; 65–70.
RUNNARD PJV, et al. A randomised placebo-controlled trial of prolonged prednisolone administration to patients with HELLP syndrome remote from term. European Journal of Obstetrics & Gynecology and Reproductive Biology, 2006; 128: 187–93.
SHAHZAD N, et al. Comparison of dexamethasone versus betamethasone for the management of females with HELLP syndrome. Pakistan J Med Heal Sci, 2017; 11(2): 593–7.
SOUZA R, et al. Diagnóstico e conduta na Síndrome HELLP. Rev Med Minas Gerais, 2009; 19: 30–3.
STONE JH. Hospital HELLP Syndrome: Hemolysis, Elevated Liver Enzymes, and Low Platelets. JAMA, 1998; 280(6): 559–62.
TAKAHASHI A, et al. Effects of high-dose dexamethasone in postpartum women with class 1 haemolysis, elevated liver enzymes and low platelets (HELLP) syndrome. J Obstet Gynae (Lahore), 2018; 0(0): 1–5.
WALLACE K, et al. Seeking the mechanism (s) of action for corticosteroids in HELLP syndrome: SMASH study. YMOB, 2013; 208(5): 380.e1-380.e8.
WEINSTEIN L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: A severe consequence of hypertension in pregnancy. Am J Obstet Gynecol, 1982; 142(2): 159–67.
YILDIRIM G, et al. HELLP Syndrome: 8 Years of Experience from a Tertiary Referral Center in Western Turkey. Hypertens Pregnancy, 2012; 31(3): 316–26.
